×
Customize
?
Start
Cancer Types
Quick Links
Award Programs
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Leukemia
Kristie L. Kahl
Time-limited treatment could be the new wave of research in the treatment of chronic lymphocytic leukemia (CLL), according to Nicole Lamanna, M.D.
Jessica Skarzynski
Here are the top 5 CURE stories for February 2019.
Beth Fand Incollingo
Brian Boyle, who plays center for the New Jersey Devils, has announced that his blood cancer is in remission.
Kristie L. Kahl
The Food and Drug Administration granted a priority review to Tibsovo (ivosidenib) for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) with an IDH1 mutation who are not eligible for standard therapy.
Understanding CLL as a chronic disease.
Knowing treatment options and the possibilities of supportive care.
Utilizing clinical trials and understanding potential side effects and complications.
Finding follow-up care and emotional support.
Serving as a caregiver for a loved one going through a CLL diagnosis and treatment while utilizing resources to take care of oneself.